1. Ghei M, Mihailescu M, Levinson D. Pathogenesis of hyperuricemia: recent advances. Curr Rheumatol Rep 2002;4:270–274PMID : 12010614.
2. Dai SM, Han XH, Zhao DB, Shi YQ, Liu Y, Meng JM. Prevalence of rheumatic symptoms, rheumatoid arthritis, ankylosing spondylitis, and gout in Shanghai, China: a COPCORD study. J Rheumatol 2003;30:2245–2251PMID : 14528524.
3. Chang HY, Pan WH, Yeh WT, Tsai KS. Hyperuricemia and gout in Taiwan: results from the Nutritional and Health Survey in Taiwan (1993-96). J Rheumatol 2001;28:1640–1646PMID : 11469473.
4. Yoo B. Serum uric acid levels in Korean adult population and their correlates. J Korean Rheum Assoc 1995;2:60–68.
5. Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol 2002;29:2403–2406PMID : 12415600.
6. Takahashi S, Yamamoto T, Moriwaki Y, Tsutsumi Z, Higashino K. Impaired lipoprotein metabolism in patients with primary gout: influence of alcohol intake and body weight. Br J Rheumatol 1994;33:731–734PMID : 8055199.
7. Adkins JC, Faulds D. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs 1997;54:615–633PMID : 9339964.
8. Desager JP, Hulhoven R, Harvengt C. Uricosuric effect of fenofibrate in healthy volunteers. J Clin Pharmacol 1980;20:560–564PMID : 7440763.
9. Feher MD, Hepburn AL, Hogarth MB, Ball SG, Kaye AE. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology 2003;42:321–325PMID : 12595630.
10. Noguchi Y, Tatsuno I, Suyama K, Shibata T, Yoshida T, Otsuka Y, Fuse M, Takeo C, Saito Y. Effect of fenofibrate on uric acid metabolism in Japanese hyperlipidemic patients. J Atheroscler Thromb 2004;11:335–340PMID : 15644587.
11. Desager JP, Hulhoven R, Harvengt C. Uricosuric effect of fenofibrate in healthy volunteers. J Clin Pharmacol 1980;20:560–564PMID : 7440763.
13. Bastow MD, Durrington PN, Ishola M. Hypertriglyceridemia and hyperuricemia: effect of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. Metabolism 1988;37:217–220PMID : 3278190.
14. de la Serna G, Cadarso C. Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia. Clin Pharmacol Ther 1999;66:166–172PMID : 10460070.
15. Day AP, Feher MD, Chopra R, Mayne PD. The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities. Metabolism 1993;42:839–842PMID : 8102192.
17. Ganotakis E, Tsimihodimos V, Bairaktari E, Rizos E, Athyros V, Seferiades C, Elisaf M. Effect of various fibrates on serum alkaline phosphatase activity. Atherosclerosis 2002;165:187–188PMID : 12208487.
18. Papadakis JA, Ganotakis ES, Jagroop IA, Winder AF, Mikhailidis DP. Statin+fibrate combination therapy: fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. Int J Cardiol 1999;69:237–244PMID : 10402106.
19. Maesaka JK, Fishbane S. Regulation of renal urate excretion: a critical review. Am J Kidney Dis 1998;32:917–933PMID : 9856507.
20. Schmidt MI, Watson RI, Duncan BB, Metcalf P, Brancati FL, Sharrett AR, Davis CE, Heiss G. Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Metabolism 1996;45:699–706PMID : 8637443.
22. Collantes Estevez E, Pineda Priego M, Anon Barbudo J, Sanchez Guijo P. Hyperuricemia-hyperlipidemia association in the absence of obesity and alcohol abuse. Clin Rheumatol 1990;9:28–31PMID : 2335049.
23. Tinahones JF, Perez-Lindon G, C-Soriguer FJ, Pareja A, Sanchez-Guijo P, Collantes E. Dietary alterations in plasma very low density lipoprotein levels modify renal excretion of urates in hyperuricemic-hypertriglyceridemic patients. J Clin Endocrinol Metab 1997;82:1188–1191PMID : 9100594.
24. Ledwith BJ, Pauley CJ, Wagner LK, Rokos CL, Alberts DW, Manam S. Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecanoylphorbol 12, 13-myristate-type tumor promoters in immortalized mouse liver cells. J Biol Chem 1997;272:3707–3714PMID : 9013627.